StreetInsider.com News Articles

eXoZymes picks Curia Global to scale NCT manufacturing process

Tue, 08 Sep 2026 10:23:12 -0400

eXoZymes Inc. (NASDAQ: EXOZ) has entered into an agreement with Curia Global, Inc. to transfer and scale its NCT manufacturing process toward commercial production, according to a press release from the company.

Under the agreement, eXoZymes will transfer its NCT manufacturing process to Curia, which will scale the process at its facilities in León, Spain, and Rozzano, Italy. The work includes cross-validation of eXoZymes' enzyme fermentation, cell-free reaction, and purification processes. The program also includes process modeling and engineering analysis to define a path to larger-scale manufacturing.

The program is expected to begin in the fourth quarter of 2026 and is designed

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Tue, 08 Sep 2026 10:20:00 -0400

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027

LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technology

The agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful pilot-scale validation toward commercial manufacturing.

Damien

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Tue, 08 Sep 2026 10:20:00 -0400

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027

The agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful pilot-scale validation toward commercial manufacturing.

Damien

Form 4 EXOZYMES INC. For: Aug 19 Filed by: Perriman Damien Alan

Tue, 25 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260825/26976034.html

Form 4 EXOZYMES INC. For: Aug 19 Filed by: Perriman Damien Alan

Tue, 25 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260825/26976034.html

Form 4 EXOZYMES INC. For: Aug 19 Filed by: Korman Tyler Paz

Tue, 25 Aug 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975948.html

Form 4 EXOZYMES INC. For: Aug 19 Filed by: Korman Tyler Paz

Tue, 25 Aug 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975948.html

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

Thu, 20 Aug 2026 16:10:00 -0400

Management to host Q2 2026 update at 5PM ET / 2PM PT, today.

LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.

Michael Heltzen, CEO of eXoZymes, states, "We have taken a molecule from

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

Thu, 20 Aug 2026 16:10:00 -0400

Management to host Q2 2026 update at 5PM ET / 2PM PT, today.

LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.
Michael Heltzen, CEO of eXoZymes, states, "We have taken a molecule from

eXoZymes reports 10-fold productivity gain in NCT manufacturing

Tue, 18 Aug 2026 16:31:30 -0400

eXoZymes Inc. (NASDAQ: EXOZ) announced improvements to its manufacturing process for N-trans-caffeoyltyramine (NCT), a compound the company is developing for nutraceutical and pharmaceutical applications.
According to a press release from the Los Angeles-based company, the optimized process produced approximately 67% more NCT per liter compared to a previously announced 100-liter pilot run, while reducing reaction time by more than 80%. The company said these combined changes resulted in a tenfold increase in manufacturing productivity.
eXoZymes said internal process-cost assessments indicate the estimated manufacturing cost equivalent has declined more than 100 times from the first version of the NCT process to the current

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

Tue, 18 Aug 2026 16:30:00 -0400

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.
Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
The new process produced approximately 67% more NCT per liter than the previously announced 100-liter pilot run.
Reaction time was reduced by over 80%, allowing substantially more product to be produced in less time.
The improvements support a more scalable and efficient manufacturing process as eXoZymes prepares for technology transfer to future commercial partners.

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

Tue, 18 Aug 2026 16:30:00 -0400

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.
Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
The new process produced approximately 67% more NCT per liter than the previously announced 100-liter pilot run.
Reaction time was reduced by over 80%, allowing substantially more product to be produced in less time.
The improvements support a more scalable and efficient manufacturing process as eXoZymes prepares for technology transfer to future commercial partners.

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

MDB Capital Holdings Provides Second Quarter 2026 Update

Thu, 13 Aug 2026 16:05:00 -0400

Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments.

First Six Months of 2026 and Subsequent Operational Highlights

Completed $20 million IPO for Buda Juice (NYSE American: BUDA) as the sole bookrunner and underwriter, our 18^th consecutive successful IPO.

Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners

Form 10-Q EXOZYMES INC. For: Jun 30

Thu, 13 Aug 2026 15:50:00 -0400
si-local-file:///var/storage/secattach/20260813/26920404.html

Form 10-Q EXOZYMES INC. For: Jun 30

Thu, 13 Aug 2026 15:50:00 -0400
si-local-file:///var/storage/secattach/20260813/26920404.html

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

Tue, 11 Aug 2026 16:10:00 -0400

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.

LOS ANGELES, CA / ACCESS Newswire / August 11, 2026 / CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

Tue, 11 Aug 2026 16:10:00 -0400

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.

LOS ANGELES, CA / ACCESS Newswire / August 11, 2026 / CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team

eXoZymes selected for DoE Genesis Mission with $147K in funding

Thu, 23 Jul 2026 16:16:53 -0400

eXoZymes Inc. (NASDAQ: EXOZ) has been selected to participate in the U.S. Department of Energy's Genesis Mission, a nationwide initiative aimed at accelerating scientific discovery through artificial intelligence, according to a press release from the company.
The nine-month project carries total funding of approximately $747,000, with $147,000 awarded directly to eXoZymes. As part of the collaboration, eXoZymes will work with researchers at Lawrence Berkeley National Laboratory, including Dr. Edward Baidoo and Dr. Hector Garcia Martin, to develop AI-powered digital twins for cell-free biomanufacturing processes.
Under the project, eXoZymes will generate experimental datasets from cell-free enzymatic pathways. Dr. Baidoo's team will develop metabolomic

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

Thu, 23 Jul 2026 16:15:00 -0400

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.
The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes
Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.
Provides access to the DOE Genesis Mission Platform, including advanced AI models, AI agents and high-performance computing infrastructure to accelerate future platform development.

LOS ANGELES, CA / ACCESS Newswire / July 23, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ)

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

Thu, 23 Jul 2026 16:15:00 -0400

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.
The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes
Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.
Provides access to the DOE Genesis Mission Platform, including advanced AI models, AI agents and high-performance computing infrastructure to accelerate future platform development.

LOS ANGELES, CA / ACCESS Newswire / July 23, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ)